[96a5a0]: / output / allTrials / logical / NCT02538666_logical.json

Download this file

354 lines (354 with data), 15.7 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
{
"info": {
"nct_id": "NCT02538666",
"official_title": "A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 451)",
"inclusion_criteria": "* Subjects with histologically or cytologically confirmed extensive stage disease SCLC\n* Ongoing response of stable disease or better following 4 cycles of platinum-based first line chemotherapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Subjects with symptomatic Central Nervous System (CNS) metastases\n* Subjects receiving consolidative chest radiation\n* Subjects with active, known, or suspected autoimmune disease are excluded\n* All side effects attributed to prior anti-cancer therapy must have resolved to Grade 1 or baseline\n\nOther protocol-defined inclusion/exclusion criteria apply",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"identified_line": {
"line": "* Subjects with histologically or cytologically confirmed extensive stage disease SCLC",
"criterions": [
{
"exact_snippets": "histologically or cytologically confirmed extensive stage disease SCLC",
"criterion": "extensive stage disease SCLC",
"requirement": {
"requirement_type": "confirmation method",
"expected_value": [
"histologically",
"cytologically"
]
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "histologically or cytologically confirmed extensive stage disease SCLC",
"criterion": "extensive stage disease SCLC",
"requirement": {
"requirement_type": "confirmation method",
"expected_value": [
"histologically",
"cytologically"
]
}
}
]
}
},
{
"identified_line": {
"line": "* Ongoing response of stable disease or better following 4 cycles of platinum-based first line chemotherapy",
"criterions": [
{
"exact_snippets": "Ongoing response of stable disease or better",
"criterion": "disease response",
"requirement": {
"requirement_type": "response level",
"expected_value": [
"stable disease",
"better"
]
}
},
{
"exact_snippets": "following 4 cycles of platinum-based first line chemotherapy",
"criterion": "platinum-based first line chemotherapy",
"requirement": {
"requirement_type": "completion",
"expected_value": "4 cycles"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Ongoing response of stable disease or better",
"criterion": "disease response",
"requirement": {
"requirement_type": "response level",
"expected_value": [
"stable disease",
"better"
]
}
},
{
"exact_snippets": "following 4 cycles of platinum-based first line chemotherapy",
"criterion": "platinum-based first line chemotherapy",
"requirement": {
"requirement_type": "completion",
"expected_value": "4 cycles"
}
}
]
}
},
{
"identified_line": {
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
}
},
{
"identified_line": {
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
}
}
],
"exclusion_lines": [
{
"identified_line": {
"line": "* Subjects with symptomatic Central Nervous System (CNS) metastases",
"criterions": [
{
"exact_snippets": "symptomatic Central Nervous System (CNS) metastases",
"criterion": "Central Nervous System (CNS) metastases",
"requirement": {
"requirement_type": "symptomatic",
"expected_value": true
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "symptomatic Central Nervous System (CNS) metastases",
"criterion": "Central Nervous System (CNS) metastases",
"requirement": {
"requirement_type": "symptomatic",
"expected_value": true
}
}
}
},
{
"identified_line": {
"line": "* Subjects receiving consolidative chest radiation",
"criterions": [
{
"exact_snippets": "Subjects receiving consolidative chest radiation",
"criterion": "consolidative chest radiation",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "Subjects receiving consolidative chest radiation",
"criterion": "consolidative chest radiation",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
}
},
{
"identified_line": {
"line": "* All side effects attributed to prior anti-cancer therapy must have resolved to Grade 1 or baseline",
"criterions": [
{
"exact_snippets": "All side effects attributed to prior anti-cancer therapy must have resolved to Grade 1 or baseline",
"criterion": "side effects from prior anti-cancer therapy",
"requirement": {
"requirement_type": "severity",
"expected_value": "Grade 1 or baseline"
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "All side effects attributed to prior anti-cancer therapy must have resolved to Grade 1 or baseline",
"criterion": "side effects from prior anti-cancer therapy",
"requirement": {
"requirement_type": "severity",
"expected_value": "Grade 1 or baseline"
}
}
}
},
{
"identified_line": {
"line": "Other protocol-defined inclusion/exclusion criteria apply",
"criterions": [
{
"exact_snippets": "Other protocol-defined inclusion/exclusion criteria apply",
"criterion": "protocol-defined inclusion/exclusion criteria",
"requirement": {
"requirement_type": "application",
"expected_value": true
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "Other protocol-defined inclusion/exclusion criteria apply",
"criterion": "protocol-defined inclusion/exclusion criteria",
"requirement": {
"requirement_type": "application",
"expected_value": true
}
}
}
}
],
"miscellaneous_lines": [],
"failed_inclusion": [
{
"identified_line": {
"line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
"criterion": "ECOG performance status",
"requirement": {
"requirement_type": "value",
"expected_value": [
"0",
"1"
]
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
"criterion": "ECOG performance status",
"requirement": {
"requirement_type": "value",
"expected_value": "0"
}
},
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
"criterion": "ECOG performance status",
"requirement": {
"requirement_type": "value",
"expected_value": "1"
}
}
]
}
}
],
"failed_exclusion": [
{
"identified_line": {
"line": "* Subjects with active, known, or suspected autoimmune disease are excluded",
"criterions": [
{
"exact_snippets": "active, known, or suspected autoimmune disease",
"criterion": "autoimmune disease",
"requirement": {
"requirement_type": "status",
"expected_value": [
"active",
"known",
"suspected"
]
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"not_criteria": {
"or_criteria": [
{
"exact_snippets": "active, known, or suspected autoimmune disease",
"criterion": "autoimmune disease",
"requirement": {
"requirement_type": "status",
"expected_value": "active"
}
},
{
"exact_snippets": "active, known, or suspected autoimmune disease",
"criterion": "autoimmune disease",
"requirement": {
"requirement_type": "status",
"expected_value": "known"
}
},
{
"exact_snippets": "active, known, or suspected autoimmune disease",
"criterion": "autoimmune disease",
"requirement": {
"requirement_type": "status",
"expected_value": "suspected"
}
}
]
}
}
]
}
}
],
"failed_miscellaneous": []
}